In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis-Reference-Cited by-同舟云学术

In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis

Published:2006-09 Issue:9 Volume:50 Page:3170-3172
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Vera-Cabrera Lucio¹,Gonzalez Eva¹,Rendon Adrian²,Ocampo-Candiani Jorge¹,Welsh Oliverio¹,Velazquez-Moreno Victor M.¹,Hak Choi Sung³,Molina-Torres Carmen¹

Affiliation:

1. Servicio de Dermatología, Hospital Universitario José E. González, Monterrey, N.L., México 64460

2. Servicio de Neumología, Hospital Universitario José E. González, Monterrey, N.L., México 64460

3. Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Korea

Abstract

ABSTRACT The in vitro activities of DA-7157, a novel oxazolidinone, against clinical isolates of Nocardia brasiliensis and Mycobacterium tuberculosis were determined. Equal MIC 50 s and MIC 90 s (0.25 and 0.5 μg/ml, respectively) were found for susceptible and multidrug-resistant isolates of M. tuberculosis . The N. brasiliensis isolates showed an MIC 90 of 1 μg/ml and an MIC 50 of 1 μg/ml. The DA-7157 prodrug, DA-7218, exhibited similar MICs for M. tuberculosis but fivefold-higher MICs for N. brasiliensis .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00571-06

Reference10 articles.

1. Fortun, J., P. Martin-Davila, E. Navas, M. J. Perez-Elias, J. Cobo, M. Tato, E. G. De la Pedrosa, E. Gomez-Mampaso, and S. Moreno. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother.56:180-185.

2. In Vitro and In Vivo Activities of Antimicrobials against Nocardia brasiliensis

3. Jones, R. N., J. E. Ross, T. R. Fritsche, and H. S. Sader. 2006. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolates from 16 nations. J. Antimicrob. Chemother.57:279-287.

4. López-Martínez, R., L. J. Méndez-Tovar, P. Lavalle, O. Welsh, A. Saul, and E. Macotela-Ruíz. 1992. Epidemiología del micetoma en México: estudio de 2105 casos. Gac. Med. Mex.128:477-481.

5. Moylett, E. H., S. E. Pacheco, B. A. Brown-Elliott, T. R. Perry, E. S. Buescher, M. C. Birmingham, J. J. Schentag, J. F. Gimbel, A. Apodaca, M. A. Schwartz, R. M. Rakita, and R. J. Wallace, Jr. 2003. Clinical experience with linezolid for the treatment of nocardia infection. Clin. Infect. Dis.36:313-318.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?;Pharmaceutics;2024-06-17

2. In vitro activity of tedizolid against 43 species of Nocardia species;Scientific Reports;2024-03-04

3. New Oxazolidinone: Tedizolid;New Antimicrobials: For the Present and the Future;2023

4. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China;Frontiers in Medicine;2022-11-29

5. Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy;Frontiers in Pharmacology;2022-10-18